Author + information
- Received June 12, 2018
- Revision received July 24, 2018
- Accepted July 25, 2018
- Published online March 4, 2019.
- Rebecca T. Hahn, MDa,∗ (, )
- Michael Nabauer, MDb,
- Michel Zuber, MDc,
- Tamim M. Nazif, MDa,
- Jörg Hausleiter, MDb,
- Maurizio Taramasso, MD, PhDc,
- Alberto Pozzoli, MDc,
- Isaac George, MDa,
- Susheel Kodali, MDa,
- Vinayak Bapat, CTha and
- Francesco Maisano, MDc
- aColumbia University Medical Center, New York Presbyterian Hospital, New York, New York
- bMedizinische Klinik und Poliklinik I, Klinikum der Universität, Munich, Germany
- cHeart Center, Zürich University Hospital, University of Zürich. Zürich, Switzerland
- ↵∗Address for correspondence:
Dr. Rebecca T. Hahn, Columbia University Medical Center, New York-Presbyterian Hospital, 177 Fort Washington Avenue, New York, New York 10032.
Interest in the transcatheter solutions for tricuspid regurgitation has gained momentum given the limited indications for and high in-hospital mortality associated with isolated surgical intervention. Advanced imaging techniques to guide the procedures are the key to technical success. The following overview of the imaging requirements of selected devices is intended to give a glimpse into the complex procedures now possible with imaging guidance.
Dr. Hahn is the principal investigator for the SCOUT trial for which she receives no compensation; the Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for which she receives no direct industry compensation; and has received personal fees from Abbott Vascular, Boston Scientific, Bayliss, Navigate, Philips Healthcare, and Siemens Healthineers. Dr. Nabauer has received personal fees from Abbott Vascular. Dr. Nazif has received personal fees from Edwards Lifesciences, Boston Scientific, and Medtronic. Dr. Hausleiter has received personal fees from Abbott Vascular and Edwards Lifesciences. Dr. Taramasso has received personal fees from Abbott and 4Tech. Dr. Kodali has received personal fees from Duna Biotech, Thubrikar Aortic Valve Inc., Claret Medical, Meril Lifesciences, and Abbott. Dr. Bapat has received personal fees from Medtronic and Edwards Lifesciences. Dr. Maisano has received grants and personal fees from Abbott, Edwards Lifesciences, Medtronic, and Boston Scientific; and is a cofounder of 4Tech. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received June 12, 2018.
- Revision received July 24, 2018.
- Accepted July 25, 2018.
- 2019 American College of Cardiology Foundation